Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | COMT | P21964 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.32 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.32 |
| ▸ | KIT | P10721 | 1/20 | 0.30 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.30 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.30 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.30 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.30 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20187336 | 0.68 | COMT (0.40) | COMTALDH1A1POLBSMN1; SMN2PDE3B | |
| Hydrochloric Acid SCHEMBL30007311 | 0.67 | COMT (0.39) | COMTALDH1A1POLBSMN1; SMN2PDE3B | |
| SCHEMBL14996664 | 0.60 | POLB (0.54) | COMTALDH1A1POLBSMN1; SMN2USP30 | |
| SCHEMBL27557137 | 0.59 | COMT (0.36) | COMTALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL16321045 | 0.59 | ALDH1A1 (0.44) | COMTALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL27904187 | 0.59 | COMT (0.45) | COMTALDH1A1POLBSMN1; SMN2FGFR1 | |
| SCHEMBL18124160 | 0.59 | COMT (0.45) | COMTALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL14996594 | 0.59 | SMN1; SMN2 (0.51) | COMTALDH1A1POLBSMN1; SMN2USP30 | |
| SCHEMBL19329608 | 0.59 | GAA (0.37) | COMTALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL3761896 | 0.59 | COMT (0.49) | COMTALDH1A1SMN1; SMN2USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110234638-B | Heteroaryl phenoxy benzamide KAPPA opioid ligands | 辉瑞大药厂 | 2022-10-21 | — | — | CN | disclosed |
| EP-3544972-A1 | HETEROARYLPHENOXY BENZAMIDE KAPPA OPIOID LIGANDS | Pfizer Inc (US) | 2019-10-02 | — | — | EP | disclosed |
| US-10316021-B2 | Heteroarylphenoxy benzamide kappa opioid ligands | PFIZER INC. (US) | 2019-06-11 | — | — | US | disclosed |
| US-10316021-B2 | Heteroarylphenoxy benzamide kappa opioid ligands | PFIZER INC. (US) | 2019-06-11 | — | — | US | disclosed |
| US-20180148432-A1 | HETEROARYLPHENOXY BENZAMIDE KAPPA OPIOID LIGANDS | PFIZER INC. (US) | 2018-05-31 | — | — | US | disclosed |
| US-20180148432-A1 | HETEROARYLPHENOXY BENZAMIDE KAPPA OPIOID LIGANDS | PFIZER INC. (US) | 2018-05-31 | — | — | US | disclosed |
| US-20180148432-A1 | HETEROARYLPHENOXY BENZAMIDE KAPPA OPIOID LIGANDS | PFIZER INC. (US) | 2018-05-31 | — | — | US | disclosed |
| WO-2018096510-A1 | HETEROARYLPHENOXY BENZAMIDE KAPPA OPIOID LIGANDS | PFIZER INC. (US) | 2018-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10316021-B2 | Heteroarylphenoxy benzamide kappa opioid ligands | OPRK1, OPRD1, OPRM1 | COMT 236/4885ALDH1A1 1595/4885POLB 3233/4885 |
| US-20180148432-A1 | HETEROARYLPHENOXY BENZAMIDE KAPPA OPIOID LIGANDS | OPRK1, OPRD1, OPRM1 | COMT 236/4885ALDH1A1 1595/4885POLB 3233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.